FOCAL SEGMENTAL GLOMERULOSCLEROSIS

This phase 2 trial tests an oral drug called ManNAc in 30 adults with primary focal segmental glomerulosclerosis (FSGS), a kidney disease that causes scarring and protein loss. Participants take ManNAc powder dissolved in water twice daily for 14 weeks. The study aims to see if t…

This study tests an oral medication called BI 764198 for people with a kidney condition called focal segmental glomerulosclerosis (FSGS). About 286 adults and teens will take either the study drug or a placebo daily for up to 2 years, while continuing their usual FSGS treatments.…

This study tests three experimental drugs—frexalimab, brivekimig, and rilzabrutinib—in people aged 16 to 75 with two rare kidney diseases: FSGS and MCD. The goal is to see if these drugs can reduce protein in the urine, a key sign of kidney damage, and help patients achieve remis…

This study tests an experimental drug called praliciguat in 60 adults with a rare kidney disease called FSGS. The goal is to see if it can reduce protein in the urine, a sign of kidney damage. Participants will first receive either the drug or a placebo for 24 weeks, then everyon…

This study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease (FSGS, MCD, or IgA nephropathy) that cause protein to leak into urine. Participants take the drug twice daily for a year. The main goal is to see if it safely reduces protein leve…

This study tests an oral drug called sparsentan in 67 children with certain kidney diseases that cause protein to leak into urine. The goal is to see if the drug safely reduces protein levels over 108 weeks. Participants must have a certain level of kidney function to join.

This study tests a noninvasive device that gently stimulates a nerve in the ear to help children with steroid-resistant nephrotic syndrome, a kidney condition that doesn't respond to standard steroids. The goal is to see if this approach is feasible and tolerable, and if it can r…

This study tests a non-invasive device that gently stimulates a nerve in the ear to see if it can help control nephrotic syndrome in children aged 3-17. The goal is to reduce relapses and the need for steroids or other immune-suppressing drugs. Thirty children will be randomly as…

This study tests whether the diabetes drug metformin can protect kidney cells in people with a rare kidney disease called FSGS. About 30 adults will receive either metformin or a placebo for 6 months, alongside their usual treatments. The goal is to see if metformin reduces kidne…

This study is for people with rare kidney diseases like Minimal Change Disease, Focal Segmental Glomerulosclerosis, and Membranous Nephropathy. Researchers will collect health information and biological samples from 1,200 participants over many years. The goal is to better unders…

This study helps people with certain kidney diseases (like nephrotic syndrome and FSGS) find clinical trials that match their specific disease profile. Researchers analyze participants' molecular data to recommend targeted therapies in ongoing trials. The goal is to improve treat…

This study is collecting medical information and biological samples (like blood, urine, and kidney tissue) from 300 people with FSGS or MCD who have had or will have a kidney transplant. The goal is to build a research biobank called RESOLVE to help scientists study why these dis…

This study aims to see if a special cell culture system can detect a substance in the blood that causes protein leakage in the urine of people with a kidney condition called nephrotic syndrome. Researchers will compare blood and urine samples from 150 participants, including pati…